ED
AVNS

Exane Derivatives’s Avanos Medical AVNS Stock Holding History

Exane Derivatives’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed -$37 – 577
2016
Q4 		$37 Hold
1
– – ﹤0.01% 588
2016
Q3 		$35 Hold
1
– – ﹤0.01% 576
2016
Q2 		$33 Hold
1
– – ﹤0.01% 512
2016
Q1 		$29 Hold
1
– – ﹤0.01% 565
2015
Q4 		$33 Hold
1
– – ﹤0.01% 477
2015
Q3 		$28 Hold
1
– – ﹤0.01% 510
2015
Q2 		$40 Hold
1
– – ﹤0.01% 505
2015
Q1 		$49 Hold
1
– – ﹤0.01% 501
2014
Q4 		$38 Buy
+1
New +$39 ﹤0.01% 509

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
SCM
Shapiro Capital Management Atlanta, Georgia $1.6B AUM 13.27% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Exane Derivatives's AVNS Position: Q1 2017 in Review

Exane Derivatives sold out of Avanos Medical (AVNS) in Q1 2017, closing a stake of 1 share — an estimated $37 sold.

Exane Derivatives first reported a position in AVNS in Q4 2014 and held it in 9 quarters. The position peaked at $49 in Q1 2015. 335 funds tracked by Wall St. Rank hold AVNS as of Q1 2017.

  • Exane Derivatives reported no remaining Avanos Medical position as of Q1 2017 after selling out during the quarter.
  • Exane Derivatives sold 1 Avanos Medical share in Q1 2017, an estimated $37.
  • Exane Derivatives first reported a position in Avanos Medical in Q4 2014 and held it in 9 quarters.
  • Exane Derivatives's Avanos Medical position peaked at $49 in Q1 2015.
  • 335 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2017.

Based on Exane Derivatives's 13F filing for Q1 2017, filed 28 Apr 2017.